Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

March 30, 2026

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

HB0043

Low dose

DRUG

HB0043

Medium dose

DRUG

HB0043

High dose

Trial Locations (1)

RECRUITING

Dermatology Hospital affiliated to Shandong First Medical University, Jinan

All Listed Sponsors

collaborator

Dermatology Hospital affiliated to Shandong First Medical University

UNKNOWN

lead

Shanghai Huaota Biopharmaceutical Co., Ltd.

INDUSTRY

NCT06895499 - Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. | Biotech Hunter | Biotech Hunter